sEH inhibitors and their use

Details sEH inhibitors and their use sEH inhibitors and their use

2011-08-09

2011-08-09

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C544S198000, C544S208000, C544S209000, C514S245000

Reexamination Certificate

active

07994317

ABSTRACT:
The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

REFERENCES:
patent: 2004/0029902 (2004-02-01), Singh et al.
patent: 1464335 (2004-10-01), None
patent: WO2009049154 (2009-04-01), None
patent: WO2009049157 (2009-04-01), None
patent: WO2009049165 (2009-04-01), None
Dorrance, Phd., Et Al.: “An Epoxide Hydrolase Inhibitor, 12-(3-Adamantan-1-Yl-Ureido)Dodecanoic Acid (AUDA), Reduces Ischemic Cerebral Infact Size in Stroke-Prone Spontaneously Hypertensive Rats” Journal of Cardiovascular Pharmacology, Dec. 2005, vol. 46, No. 6, pp. 842-848.
Fornage, Et Al.: “The Soluble Epoxide Hydrolase Gene Harbors Sequence Variation Associated With Susceptibility to and Protection From Incident Ischemic Stroke” Human Molecular Genetics, 2005, vol. 14, No. 19, pp. 2829-2837.
Fretland, Et Al.: “Epoxide Hydrolases: Biochemistry and Molecular Biology”, Chemico-Biological Interactions. 2000; vol. 129, pp. 41-59.
Imig, Et Al.: “Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension” Hypertension. 2002; vol. 39 (Part 2), pp. 690-694.
Imig, Et Al.: “An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension” Hypertension. 2005; vol. 46 (Part 2): pp. 975-981.
Imig, Et Al.: “Cardiovascular Therapeutic Aspects of Soluble Epoxide Hydrolase Inhibitors” Cardiovascular Drug Reviews. 2006; vol. 24, No. 2, pp. 169-188.
Inceoglu, Et Al.: “Inhibition of Soluble Epoxide Hydrolase Reduces LPS-Induced Thermal Hyperalgesia and Mechanical Allodynia in a Rat Model of Inflammatory Pain” Life Sciences. 2006; vol. 79, pp. 2311-2319.
Jones, P.D. Et Al.: “Synthesis and SAR of Conformationally Restricted Inhibitors of Soluble Epoxide Hydrolase” Bioorganic & Medicinal Chemistry Letters, Oct. 1, 2009, vol. 16, No. 19, pp. 5212-5216.
Jung, Et Al.: “Soluble Epoxide Hydrolase is a Main Effector of Angiotensin II-Induced Hypertension” Hypertension. 2005; vol. 45 (Part 2), pp. 759-765.
Koerner, Et Al.: “Polymorphisms in the Human Soluble Epoxide Hydrolase GeneEPHX2Linked to Neuronal Survival After Ischemic Injury” The Journal of Neuroscience. Apr. 25, 2007; vol. 27, No. 17, pp. 4642-4649.
Krotz, Et Al.: “Membrane Potential-Dependent Inhibition of Platelet Adhesion to Endothelial Cells by Epoxyeicosatrienoic Acids” Arterioscler Thrombosis Vascular Biology. 2004; vol. 24, pp. 595-600.
Lee, Et Al.: “Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study” Human Molecular Genetics. 2006; vol. 15, No. 10, pp. 1640-1649.
Loch, Et Al.: “Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase” Cell Biochemistry and Biophysics. 2007; vol. 47, pp. 87-97.
Sato, Et Al.: “Soluble Epoxide Hydrolase Variant (Glu287Arg) Modifies Plasma Total Cholesterol and Triglyceride Phenotype in Familial Hypercholesterolemia: Intrafamilial Association Study in an Eight-Generation Hyerlipidemic Kindred” Journal of Human Genetics. 2004; vol. 49, pp. 29-34.
Sinal, Et Al.: “Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation” The Journal of Biological Chemistry. 2000; vol. 275, No. 51, pp. 40504-40510.
Spector, Et Al.: “Epoxyeicosatrienoic Acids (Eets): Metabolism and Biochemical Function” Progress in Lipid Research. 2004; vol. 43, pp. 55-90.
Wei, Et Al.: “Sequence Variation in the Soluble Epoxide Hydrolase Gene and Subclinical Coronary Atherosclerosis: Interaction With Cigarette Smoking” Atherosclerosis. 2007; vol. 190, pp. 26-34.
Xu, Et Al.: “Prevention and Reversal of Cardiac Hypertrophy by Soluble Epoxide Hydrolase Inhibitors” Proceedings National Academy of Sciences. 2006; vol. 103, No. 49, pp. 18733-18738.
Zhao, Et Al.: “Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage” Journal of the American Society of Nephrology, 2004, vol. 15, pp. 1244-1253.

Affiliated with

Also associated with

Rating

sEH inhibitors and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with sEH inhibitors and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and sEH inhibitors and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2643924